Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 11/20 | 0.50 |
| ▸ | MTOR | P42345 | 9/20 | 0.50 |
| ▸ | PIK3CB | P42338 | 7/20 | 0.50 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.50 |
| ▸ | ATM | Q13315 | 8/20 | 0.47 |
| ▸ | ATR | Q13535 | 6/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | PIK3C2A | O00443 | 2/20 | 0.43 |
| ▸ | PIK3C2B | O00750 | 2/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.43 |
| ▸ | CSF1R | P07333 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.43 |
| ▸ | LTK | P29376 | 1/20 | 0.43 |
| ▸ | CDK7 | P50613 | 1/20 | 0.43 |
| ▸ | NEK2 | P51955 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2068663 | 0.87 | PIK3CD (0.51) | PIK3CDMTORPIK3CBPIK3CGPIK3CA | |
| SCHEMBL3514024 | 0.86 | MTOR (0.48) | PIK3CDMTORPIK3CBPIK3CGPIK3CA | |
| SCHEMBL7875312 | 0.85 | PIK3CD (0.51) | PIK3CDMTORPIK3CBPIK3CGPIK3CA | |
| SCHEMBL2068406 | 0.85 | MTOR (0.54) | PIK3CDMTORPIK3CBPIK3CGPIK3CA | |
| SCHEMBL2069439 | 0.85 | ATM (0.50) | PIK3CDMTORPIK3CBPIK3CGPIK3CA | |
| SCHEMBL2068686 | 0.84 | MTOR (0.53) | PIK3CDMTORPIK3CBPIK3CGPIK3CA | |
| SCHEMBL2069020 | 0.84 | ATM (0.47) | PIK3CDMTORPIK3CBPIK3CGPIK3CA | |
| SCHEMBL3516548 | 0.82 | PIK3CD (0.47) | PIK3CDMTORPIK3CBPIK3CGPIK3CA | |
| SCHEMBL2068203 | 0.82 | MTOR (0.55) | PIK3CDMTORPIK3CBPIK3CGPIK3CA | |
| SCHEMBL2066904 | 0.82 | MTOR (0.53) | PIK3CDMTORPIK3CBPIK3CGPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2438063-A1 | 1H-IMIDAZO[4,5-C]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis AG (CH) | 2012-04-11 | — | — | EP | claimed |
| WO-2010139747-A1 | 1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2010-12-09 | — | — | WO | claimed |
| US-20100311714-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS | NOVARTIS AG (CH) | 2010-12-09 | — | — | US | claimed |
| EP-2438063-A1 | 1H-IMIDAZO[4,5-C]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis AG (CH) | 2012-04-11 | — | — | EP | disclosed |
| WO-2010139747-A1 | 1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2010-12-09 | — | — | WO | disclosed |
| US-20100311714-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS | NOVARTIS AG (CH) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311714-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS | PRKCA, ABL1, MYLK2 | PIK3CD 72/4885MTOR 326/4885PIK3CB 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.